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INTRODUCTION
Epithelial ovarian cancer remains the leading cause of death from gynecologic malignancies, with high-grade serous ovarian cancer (HGSOC) the most common histological subtype (1) . Following cytoreductive surgery and platinum-based chemotherapy, ~70% of HGSOC patients relapse despite an initial response to therapy (2) . Given the practical certainty of recurrence in relapsed HGSOC, a maintenance approach was proposed to delay subsequent had significantly greater PFS benefit with olaparib maintenance than those receiving placebo (median 11.2 vs 4.3 months; HR 0.18; 95% CI 0.10 to 0.31; P<0.0001; data maturity 52%) (4) .
Overall survival improved by 3 months, which was not significant; possibly because of post-trial cross-over whereby 22.6% of placebo patients received PARPi in subsequent clinical trials following progression on placebo. Olaparib is now approved in Europe, Australia and Canada for the maintenance treatment of women with relapsed, BRCA1/2m-positive (germline or somatic) HGSOC who have had complete or partial response to platinum-based chemotherapy (5) .
Olaparib is also approved in the USA for monotherapy in patients with germline BRCA1/2m advanced HGSOC who have been treated with ≥3 prior lines of chemotherapy (6) . Proteins encoded by the BRCA1/2 genes are crucial effectors of double-strand-break DNA repair (7) ; as a result, BRCA1/2m carriers are known to be highly responsive to DNA-damaging agents, including platinum-based chemotherapies (8, 9) and PARPi (8) , although mechanisms of action and resistance to PARPi are not fully understood (10) . Other than deleterious BRCA1m or BRCA2m, there are no predictive biomarkers for sensitivity to olaparib. Data from The Cancer Genome Atlas (TCGA) and functional studies indicate that approximately half of HGSOC are homologous recombination repair (HR) defective (11) (12) (13) . PARP is involved in the repair of single-strand DNA breaks, and its inhibition can result in replication-associated double-strand breaks. Such HR-deficient cells as those found in BRCA1/2-mutated tumors, whether repaired via error-prone pathways or persistent without repair, cause further genetic instability and can lead to cell death (14) .
We hypothesize that studying HGSOC patients with prolonged response to olaparib may identify additional biomarkers of response beyond BRCA1/2m. The objective of this study was to identify and characterize long-term responders to olaparib maintenance in comparison with short-term responders in terms of clinical and molecular profile to pinpoint additional markers of response and explore potential resistance factors.
METHODS

Patient population
We investigated the molecular and clinical characteristics of long-and short-term responders randomized to maintenance olaparib or placebo in the phase II, randomized, doubleblind study of olaparib in patients with platinum-sensitive relapsed high-grade serous ovarian cancer following treatment with ≥2 lines of platinum-based chemotherapy (NCT00753545; Study 19) (3). This trial enrolled 265 patients, with 136 patients assigned to olaparib and 129 to placebo. Given that the greatest PFS benefit was at 11.2 months, we defined long-term (LT) responders, whatever their BRCA1/2 status, as having a double PFS benefit, i.e. of >2 years.
Short-term (ST) responders were defined as having PFS of <3 months, given the PFS observed in the placebo group of 4.8 months.
A second comparison/confirmation cohort from the open-label, randomized, phase II study of olaparib/carboplatin/paclitaxel with olaparib maintenance versus carboplatin/paclitaxel/observation in patients with platinum-sensitive recurrent HGSOC (NCT01081951; Study 41) was evaluated (15) . In the combination phase, 156 patients were treated (81 in the olaparib-plus-chemotherapy group and 75 in the chemotherapy-alone group) and 121 continued to maintenance or no further treatment (66 in the olaparib-plus-chemotherapy group and 55 in the chemotherapy-alone group). Given that patients in this study received olaparib with chemotherapy, the ST responders were defined as patients with PFS of <6 months, taking into account the time over which olaparib was administered with chemotherapy to assess the maintenance period.
Data collection
Clinical trial data were prospectively obtained for all treated patients ( 
Statistical analysis
Descriptive analyses from all LT and ST responders to olaparib/placebo were assessed for statistical significance. Fisher's exact or chi-squared tests were used to test for associations between individual explanatory variables and response duration (long vs short term) as appropriate. SPSS and Excel were used for all analyses. Given the exploratory data analysis, no type 1 error correction was performed.
RESULTS
Clinical data
Data were collected from 265 total patients on study for the patients with LT and ST responses to olaparib therapy or placebo as part of Study 19. Thirty-seven patients were identified as LT responders, of whom 32 (86.5%) had received olaparib. Of the 61 ST patients identified, 21 (34.4%) had received olaparib. The main characteristics are summarized in Table 1 and Table 2 . LT responders on olaparib (32 patients) had a median of three prior lines of therapy, with one-third having relapsed within 6-12 months of their penultimate platinum-based chemotherapy. Of the LT responders on olaparib, 44% (14/32) had partial responses to their most recent platinum-based chemotherapy, with residual disease evident at the time of olaparib maintenance ( Table 1 ). The other 18 of 32 (56%) LT responders on olaparib had complete response to the most recent platinum-based chemotherapy, in comparison with only five of 21 (24%) olaparib ST responders (Table 1) . Complete response to platinum-based chemotherapy at the time of olaparib maintenance was associated with LT response to olaparib (P=0.026, univariate analysis). The treatment-free interval following the penultimate platinum-based chemotherapy did not correlate with LT response (Supplementary Table 1 ). Sixty-five of 98 archival tumour samples (37 LT and 61 ST) were from primary tumours and nine of 98 were from metastases (this information was unavailable for the other 24 patients).
Receipt of olaparib over placebo was significantly associated with LT response (P<0.0001; 32/53, 60.4% vs 5/45, 11.1%). More patients treated with olaparib were LT than ST responders (P=0.052).
Molecular analysis
BRCA1/2 status (germline and somatic)
From the LT responders, 27/37 (73%) had loss-of-function mutations in BRCA1/2.
Among the 32 LT olaparib responders, BRCA1m and BRCA2m were found in 10 and 13 patients, respectively, with one patient showing deleterious mutations in both BRCA1 and BRCA2 (Table   2 and Table 3 ). All five LT responders receiving placebo were BRCA1/2m positive ( Table 2) . A greater number of BRCA1/2m was found in LT responders compared with ST responders (Table   3 ). In contrast, among the 21 olaparib ST responders, 10 were found to carry a deleterious BRCA1/2m (7 of 10 were in BRCA1; Table 2 and Table 3 ).
We further analyzed the type and location of BRCA1/2m in the olaparib cohort between LT and ST responders ( Figure 1 and Supplementary Figure 1) . Of the 17 patients on olaparib who had BRCA1m (LT and ST), nine had founder mutations (E23fs* or Q1756fs*), whereas only one patient had a founder BRCA2m (S1982fs*; ST responder group). Interestingly, among patients on olaparib, mutations in the DNA-binding domains of BRCA1 (n=1) or BRCA2 (n=4)
were only seen in the LT responder group.
BRCA1 methylation status was available for 27/37 (73%) LT responders, all of whom were negative. In contrast BRCA1 methylation status was available for 42/61 (69%) ST responders, eight of whom (19%) had BRCA1 methylation. Methylation of BRCA1 was not associated with LT olaparib response.
Homologous recombination repair deficiency
No significant difference was seen between LT and ST responders according to the HRD score ( Table 3) . Most of the patients enrolled in the study were characterized by HR-deficient status (81% of the LT and ST on olaparib). Among data available for 26 of the 32 (81%) LT responders on olaparib, 25 patients (96%) had HR deficiency, in contrast to 76% of the ST olaparib responders ( Table 2 Table 2) . Furthermore, four patients had alterations in PTEN (2 homozygous deletions, 1 somatic variant and 1 functional intergenic truncation), all of whom were LT responders on olaparib. These PTEN alterations co-occurred with BRCA1/2 mutation for three of the patients, only one LT patient had a PTEN mutation in the absence of a BRCA1/2 mutation. In contrast, no PTEN alterations were seen in the ST responder group (Supplementary Table 3) . Interestingly, three patients randomized to the placebo arm had PTEN alterations and were ST responders (Supplementary Table 3 ).
Validation cohort
LT and ST responders from Study 41 were identified and analyzed ( Figure 3 and Supplementary Table 4 ). In total, 19 LT responders were identified and all were in the olaparib arm. Olaparib maintenance was also significantly associated with LT responders (P<0.0001).
BRCA1/2m was statistically correlated with LT response to olaparib (Supplementary Table 4 ).
BRCA1m and BRCA2m were observed in six and five LT responders, respectively. The 11 ST patients were all BRCA1/2 wild-type.
DISCUSSION
There are limited data describing ovarian cancer patients who experience prolonged benefit from PARP inhibition, other than evidence for the role played by deleterious mutations in BRCA1/2. Defective DNA repair via homologous recombination repair deficiency is a fundamental vulnerability in HGSOC and can be exploited with PARPi, such as olaparib, by induction of cancer-specific synthetic lethality (19) . Examination of broader clinical and molecular data of extreme responders may uncover potential biomarkers of response (20) . We 
genotypes (22). Previous studies have shown that BRCA2m is associated with prolonged survival in invasive epithelial ovarian cancer (23). In 2012, Liu et al showed that the presence of a
BRCA2m was associated with longer survival and better therapy response than a BRCA1m in HGSOC (24) . Many LT olaparib responders had a BRCA2m in the RAD51-binding domain, described as a frequent site of BRCA2m by TCGA (11), but also in DNA-binding sites ( Figure 3 ).
As such, mutations in the RAD51 region are expected to attenuate or abolish interactions with RAD51, resulting in failure to load RAD51 to DNA-damage sites (24) . Our data also suggest that silencing of BRCA1 through promoter methylation does not result in improvement in response to platinum-based chemotherapy or to sequential chemotherapy and maintenance olaparib therapy, as previously suggested by TCGA and other publications showing a lack of survival benefit and correlation with platinum sensitivity (11, 25) .
However, our study did not identify a potential mechanism involved in the small group of BRCA1/2 wild-type patients who had a LT benefit to olaparib maintenance, currently not eligible for olaparib in clinical practice. Beyond BRCA1/2m, there have been a number of mechanisms of HR deficiency described that may correlate with platinum and PARP response (11) , and newly developed homologous recombination repair panels have assessed several additional novel genes, including NBN, MRE11, RAD50, RAD51C, PALB2, BARD1, and BRIP1 (19, 26, 27) . Our results
show that the majority of patients enrolled in the study were HR deficient, a potential enrichment due to the selection of HGSOC patients based on platinum-sensitivity recurrence and objective response to platinum. The phase II study ARIEL2 investigating rucaparib (another PARPi) monotherapy in patients with recurrent platinum-sensitive HGSOC has confirmed BRCA1/2m as a biomarker of response, as well as genomic LOH, a potential predictive surrogate marker for HR deficiency (28) . It was hypothesized that the inability of the cell to perform HR repair leads to genomic scarring and LOH, thus enabling the use of high LOH as a signature of HR deficiency. However, no data are currently available for LT responders and PARPi progression.
Recently, the maintenance phase III study of niraparib, another PARPi, showed increased PFS in all patients -germline BRCA1/2 patients (the group with greatest benefit), and non-BRCA1/2 carriers (comprising of both HRD-positive as well as HRD-negative tumors) (29) . Eligible patients had to have achieved response following 4 to 6 cycles of platinum-based chemotherapy with a CA-125 in the normal range or reduced by 90% for at least 7 days; an absence of measurable disease greater than 2cm at study commencement. Consistent with our findings, the PFS benefit to PARPi is driven by minimal residual disease (complete response prior maintenance), BRCA1/2 mutation and HRD-positive tumors, though not exclusively. The current HR deficiency assays available did not completely identify biomarkers involved in response or resistance to PARPi.
Interestingly, four genetic alterations in the PTEN gene were observed, of which three were associated with BRCA1/2m in the LT responders on olaparib but none in the ST responder group. Moreover, in the placebo arm, three patients with PTEN alterations had disease progression within 3 months (Supplementary Table 3 Pennington et al reported that germline and somatic mutations in 13 HR genes predict platinum response and survival in ovarian, fallopian tube and peritoneal carcinomas (26) . These signatures need prospective validation.
CONCLUSION
This is the first study contrasting LT with ST responders to PARPi in terms of clinical and molecular data. Our results show that LT response to olaparib has been observed in platinum-sensitive recurrent HGSOC. This durable response may be multifactorial and driven by germline and somatic BRCA1/2m. This pilot study warrants a larger cohort to characterize LT responders. A study is ongoing to identify LT and ST responders to olaparib and allows for additional tumor tissue collection for analysis (NCT02489058).
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